Actions of Ipm Wound in details
Description: Ipm Wound is a polysaccharide which functions as a tissue lubricant. It is widely used in ophthalmic surgery because it forms a viscoelastic solution in water which makes it a suitable substitute for aqueous and vitreous humour.
Pharmacokinetics:
Distribution: Widely distributed in body tissues and intracellular fluids.
Excretion:
Ophthalmic, via Canal of Schlemm.
How should I take Ipm Wound?
This section provides information on the proper use of a number of products that contain hyaluronate sodium. It may not be specific to Ipm Wound. Please read with care.
Dosing
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For parenteral dosage form (injection):
- For knee pain caused by osteoarthritis:
- Adults—By injection into the knee, 20 milligrams (mg) once a week (one week apart) for a total of five injections.
- Children—Use and dose must be determined by your doctor.
- For knee pain caused by osteoarthritis:
Ipm Wound pharmacology
Clinical Studies
12 Week Multicenter Clinical Trial
The safety and effectiveness of Ipm Wound as a treatment for pain in OA of the knee was investigated in a multicenter clinical trial conducted in Germany.
Study Design
The clinical investigation was a prospective randomized, double blinded, active control (commercially available hyaluronan) study conducted at 10 centers in Germany. A total of 321 patients with stage 2 – 3 osteoarthritis of the knee according to the Kellgren and Lawrence grading system, meeting the Altman Criteria for Classification of Idiopathic Osteoarthritis of the knee, and scoring an average score of 41 – 80 mm on the WOMAC VAS pain index were randomized into groups of equal size to receive either Ipm Wound (160 patients) or the active control (161 patients).
Patient Population And Demographics
The demographics of trial participants were comparable across treatment groups with regard to age, gender, Kellgren and Lawrence grading system, stiffness, crepitus, bony enlargement, and no palpable warmth. Table 5 lists the demographics of the patient population.
Table 5: Patient Baseline Characteristics
Secondary Endpoints
Table 8: OARSI Responder Rates Using 50-foot Walk Test (ITT)
| Visit Response/ Statistics | Saline N=295 | Ipm Wound N=291 | All Treatments N=586 | Overall Comparison (2-sided 95% Lower and Upper Bound of Confidence Interval of Odds Ratio) difference=least square mean difference |
No significant treatment group differences were observed in the change in number of study-specific acetaminophen tablets used per week or in the proportion of subjects who were pain free at Week 26 or last visit.
Reviews
The results of a survey conducted on ndrugs.com for Ipm Wound are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ipm Wound. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported administration
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
